keyword
MENU ▼
Read by QxMD icon Read
search

Myelome

keyword
https://www.readbyqxmd.com/read/29578426/dysfunction-of-various-organ-systems-induced-by-sepsis-with-underlying-severe-myelomic-diseases-and-prostate-cancer-case-report
#1
L Ratiani, N Intskirveli, L Goliadze, T Chkhikvadze, L Koptonashvili, E Khuchua
A 65-year-old male patient, unconscious, was admitted into the clinic by the Ambulance. From the patient's medical history it was revealed that several hours before the admission in the clinic the following symptoms were present: shortness of breath, fever, hypotonia, consciousness inhibition, because of which emergency brigade was called and was brought by the Emergency Brigade. The history is loaded by chronic pathologies: myeloma disease, prostate cancer, ciliary arrhythmia, heart failure; received several courses of polichemotherapy, last ten days has been treated for pneumonia with antibiotics of ceftriaxone group in outpatient setting...
February 2018: Georgian Medical News
https://www.readbyqxmd.com/read/27855381/multiples-myelom-asco-2016-best%C3%A3-tigung-der-aszt-und-neue-daten-zur-systemischen-therapie
#2
(no author information available yet)
No abstract text is available yet for this article.
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27492696/ifm-intergroupe-francophone-du-my%C3%A3-lome-recommendations-for-uniform-interpretation-of-serum-and-urine-protein-electrophoresis-in-multiple-myeloma-diagnosis-and-follow-up
#3
Thomas Dejoie, Daniela Lakomy, Hélène Caillon, Brigitte Pegourié, Olivier Decaux
Serum and urine proteins electrophoresis take a major place in multiple myeloma management, at time of diagnosis, during follow-up for treatment response evaluation and also in detection of relapse. The Intergroupe francophone du myélome (IFM) suggests recommendations to clinicians and biologists, to perform and interpret these biochemical analysis, with the objective of harmonizing practices between laboratories and improving patients' follow-up.
August 1, 2016: Annales de Biologie Clinique
https://www.readbyqxmd.com/read/27246973/rare-snps-in-receptor-tyrosine-kinases-are-negative-outcome-predictors-in-multiple-myeloma
#4
Sarah Keppler, Susann Weiβbach, Christian Langer, Stefan Knop, Jordan Pischimarov, Miriam Kull, Thorsten Stühmer, Torsten Steinbrunn, Ralf Bargou, Hermann Einsele, Andreas Rosenwald, Ellen Leich
Multiple myeloma (MM) is a plasma cell disorder that is characterized by a great genetic heterogeneity. Recent next generation sequencing studies revealed an accumulation of tumor-associated mutations in receptor tyrosine kinases (RTKs) which may also contribute to the activation of survival pathways in MM. To investigate the clinical role of RTK-mutations in MM, we deep-sequenced the coding DNA-sequence of EGFR, EPHA2, ERBB3, IGF1R, NTRK1 and NTRK2 which were previously found to be mutated in MM, in 75 uniformly treated MM patients of the "Deutsche Studiengruppe Multiples Myelom"...
June 21, 2016: Oncotarget
https://www.readbyqxmd.com/read/27114594/bortezomib-doxorubicin-cyclophosphamide-dexamethasone-induction-followed-by-stem-cell-transplantation-for-primary-plasma-cell-leukemia-a-prospective-phase-ii-study-of-the-intergroupe-francophone-du-my%C3%A3-lome
#5
MULTICENTER STUDY
Bruno Royer, Stéphane Minvielle, Momar Diouf, Murielle Roussel, Lionel Karlin, Cyrille Hulin, Bertrand Arnulf, Margaret Macro, Sylvie Cailleres, Annie Brion, Sabine Brechignac, Karim Belhadj, Marie Lorraine Chretien, Marc Wetterwald, Carine Chaleteix, Mourad Tiab, Xavier Leleu, Laurent Frenzel, Laurent Garderet, Sylvain Choquet, Jean Gabriel Fuzibet, Charles Dauriac, Luc-Matthieu Forneker, Lotfi Benboubker, Thierry Facon, Philippe Moreau, Hervé Avet-Loiseau, Jean Pierre Marolleau
PURPOSE: Primary plasma cell leukemia (pPCL) is a rare and aggressive malignancy with a poor prognosis. With conventional chemotherapy, patients typically die within 1 year. In all but one of the retrospective studies reported to date, bortezomib and lenalidomide seem to improve survival. We conducted a prospective phase II trial in patients with pPCL to assess the efficacy of an alternate regimen that combines standard chemotherapy, a proteasome inhibitor, and high-dose melphalan and autologous stem cell transplantation (HDM/ASCT) followed by either allogeneic transplantation or bortezomib/lenalidomide maintenance...
June 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27060151/a-genome-wide-association-study-identifies-a-novel-locus-for-bortezomib-induced-peripheral-neuropathy-in-european-patients-with-multiple-myeloma
#6
Florence Magrangeas, Rowan Kuiper, Hervé Avet-Loiseau, Wilfried Gouraud, Catherine Guérin-Charbonnel, Ludovic Ferrer, Alexandre Aussem, Haytham Elghazel, Jérôme Suhard, Henri Der Sakissian, Michel Attal, Nikhil C Munshi, Pieter Sonneveld, Charles Dumontet, Philippe Moreau, Mark van Duin, Loïc Campion, Stéphane Minvielle
PURPOSE: Painful peripheral neuropathy is a frequent toxicity associated with bortezomib therapy. This study aimed to identify loci that affect susceptibility to this toxicity. EXPERIMENTAL DESIGN: A genome-wide association study (GWAS) of 370,605 SNPs was performed to identify risk variants for developing severe bortezomib-induced peripheral neuropathy (BiPN) in 469 patients with multiple myeloma who received bortezomib-dexamethasone therapy prior to autologous stem cell in randomized clinical trials of the Intergroupe Francophone du Myelome (IFM) and findings were replicated in 114 patients with multiple myeloma of the HOVON-65/GMMG-HD4 clinical trial...
September 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27002117/vtd-is-superior-to-vcd-prior-to-intensive-therapy-in-multiple-myeloma-results-of-the-prospective-ifm2013-04-trial
#7
RANDOMIZED CONTROLLED TRIAL
Philippe Moreau, Cyrille Hulin, Margaret Macro, Denis Caillot, Carine Chaleteix, Murielle Roussel, Laurent Garderet, Bruno Royer, Sabine Brechignac, Mourad Tiab, Mathieu Puyade, Martine Escoffre, Anne-Marie Stoppa, Thierry Facon, Brigitte Pegourie, Driss Chaoui, Arnaud Jaccard, Borhane Slama, Gerald Marit, Karim Laribi, Pascal Godmer, Odile Luycx, Jean-Claude Eisenmann, Olivier Allangba, Mamoun Dib, Carla Araujo, Jean Fontan, Karim Belhadj, Marc Wetterwald, Véronique Dorvaux, Jean-Paul Fermand, Philippe Rodon, Brigitte Kolb, Sylvie Glaisner, Jean-Valere Malfuson, Pascal Lenain, Laetitia Biron, Lucie Planche, Helene Caillon, Herve Avet-Loiseau, Thomas Dejoie, Michel Attal
The Intergroupe Francophone du Myélome conducted a randomized trial to compare bortezomib-thalidomide-dexamethasone (VTD) with bortezomib-cyclophosphamide-dexamethasone (VCD) as induction before high-dose therapy and autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma. Overall, a total of 340 patients were centrally randomly assigned to receive VTD or VCD. After 4 cycles, on an intent-to-treat basis, 66.3% of the patients in the VTD arm achieved at least a very good partial response (primary end point) vs 56...
May 26, 2016: Blood
https://www.readbyqxmd.com/read/26787238/safe-and-prolonged-survival-with-long-term-exposure-to-pomalidomide-in-relapsed-refractory-myeloma
#8
G Fouquet, B Pegourie, M Macro, M O Petillon, L Karlin, D Caillot, M Roussel, B Arnulf, C Mathiot, G Marit, B Kolb, A M Stoppa, S Brechiniac, V Richez, P Rodon, A Banos, M Wetterwald, L Garderet, B Royer, C Hulin, L Benbouker, O Decaux, M Escoffre-Barbe, J P Fermand, M Attal, H Avet-Loiseau, P Moreau, T Facon, X Leleu
BACKGROUND: The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM). We observed that 40% of patients had a prolonged progression-free survival (PFS) and subsequently overall survival (OS). We sought to analyze the characteristics of these patients and study the effect of long exposure to pomalidomide. DESIGN: We separated the studied population into two groups: 3 months to 1 year (<1 year) and more than 1 year (≥1 year) of treatment with pomalidomide and dexamethasone based on clinical judgment and historical control studies...
May 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26659916/impact-of-renal-impairment-on-outcomes-with-lenalidomide-and-dexamethasone-treatment-in-the-first-trial-a-randomized-open-label-phase-3-trial-in-transplant-ineligible-patients-with-multiple-myeloma
#9
RANDOMIZED CONTROLLED TRIAL
Meletios A Dimopoulos, Matthew C Cheung, Murielle Roussel, Ting Liu, Barbara Gamberi, Brigitte Kolb, H Guenter Derigs, HyeonSeok Eom, Karim Belhadj, Pascal Lenain, Richard Van der Jagt, Sophie Rigaudeau, Mamoun Dib, Rachel Hall, Henry Jardel, Arnaud Jaccard, Axel Tosikyan, Lionel Karlin, William Bensinger, Rik Schots, Nicolas Leupin, Guang Chen, Jennifer Marek, Annette Ervin-Haynes, Thierry Facon
Renal impairment is associated with poor prognosis in myeloma. This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment. Transplant-ineligible patients not requiring dialysis were randomized 1:1:1 to receive continuous lenalidomide and dexamethasone until disease progression (n=535) or for 18 cycles (72 weeks; n=541), or melphalan, prednisone, and thalidomide for 12 cycles (72 weeks; n=547)...
March 2016: Haematologica
https://www.readbyqxmd.com/read/26330243/prediction-of-high-and-low-risk-multiple-myeloma-based-on-gene-expression-and-the-international-staging-system
#10
Rowan Kuiper, Mark van Duin, Martin H van Vliet, Annemiek Broijl, Bronno van der Holt, Laila El Jarari, Erik H van Beers, George Mulligan, Hervé Avet-Loiseau, Walter M Gregory, Gareth Morgan, Hartmut Goldschmidt, Henk M Lokhorst, Pieter Sonneveld
Patients with multiple myeloma have variable survival and require reliable prognostic and predictive scoring systems. Currently, clinical and biological risk markers are used independently. Here, International Staging System (ISS), fluorescence in situ hybridization (FISH) markers, and gene expression (GEP) classifiers were combined to identify novel risk classifications in a discovery/validation setting. We used the datasets of the Dutch-Belgium Hemato-Oncology Group and German-speaking Myeloma Multicenter Group (HO65/GMMG-HD4), University of Arkansas for Medical Sciences-TT2 (UAMS-TT2), UAMS-TT3, Medical Research Council-IX, Assessment of Proteasome Inhibition for Extending Remissions, and Intergroupe Francophone du Myelome (IFM-G) (total number of patients: 4750)...
October 22, 2015: Blood
https://www.readbyqxmd.com/read/25575538/pomalidomide-plus-low-dose-dexamethasone-in-multiple-myeloma-with-deletion-17p-and-or-translocation-4-14-ifm-2010-02-trial-results
#11
MULTICENTER STUDY
Xavier Leleu, Lionel Karlin, Margaret Macro, Cyrille Hulin, Laurent Garderet, Murielle Roussel, Bertrand Arnulf, Brigitte Pegourie, Brigitte Kolb, Anne Marie Stoppa, Sabine Brechiniac, Gerald Marit, Beatrice Thielemans, Brigitte Onraed, Claire Mathiot, Anne Banos, Laurence Lacotte, Mourad Tiab, Mamoun Dib, Jean-Gabriel Fuzibet, Marie Odile Petillon, Philippe Rodon, Marc Wetterwald, Bruno Royer, Laurence Legros, Lotfi Benboubker, Olivier Decaux, Martine Escoffre-Barbe, Denis Caillot, Jean Paul Fermand, Philippe Moreau, Michel Attal, Herve Avet-Loiseau, Thierry Facon
The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be safely administered to patients with end-stage relapsed/refractory multiple myeloma (RRMM). However, we observed a shorter median progression-free survival (PFS) and overall survival (OS) in these patients when characterized with adverse cytogenetics (deletion 17p and translocation [4;14]) in the Intergroupe Francophone Myélome (IFM) 2009-02 trial. We then sought to determine whether MM with adverse cytogenetics would benefit more from Pom-Dex if exposed earlier in the multicenter IFM 2010-02 trial...
February 26, 2015: Blood
https://www.readbyqxmd.com/read/25382009/-monoclonal-gammopathy-of-undetermined-significance-and-asymptomatic-multiple-myelom-in-the-year-2014%C3%A2
#12
REVIEW
Zdeněk Adam, Marta Krejčí, Luděk Pour, Eva Sevčíková, Andrea Křivanová, Zdeněk Rehák, Renata Koukalová, Zdeňka Cermáková, Jíří Vaníček, Sabina Sevčíková
Presence of monoclonal immunoglobulin in serum or urine is a relatively common event affecting about 3.2 % of people over 50. Isolated increase of only one type of free light chain, either κ or λ, is detected in 0.7-0.8 % of people over 50. Most people with monoclonal immunoglobulin meet the criteria of the so-called "mono-clonal gammopathy of undetermined significance (MGUS)". MGUS is defined by concentration of monoclonal immunoglobulin in serum < 30 g/l, number of plasma cells in the bone marrow < 10 % and the absence of symptoms of multiple myeloma and other lymphoproliferative diseases...
October 2014: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/25184863/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma
#13
RANDOMIZED CONTROLLED TRIAL
Lotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R Belch, Michele Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie Cavenagh, Catarina Geraldes, Je-Jung Lee, Christine Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell J White, Daniel Binder, Kenneth Anderson, Jean-Paul Fermand, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin-Haynes, Hervé Avet-Loiseau, Cyrille Hulin, Thierry Facon
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients)...
September 4, 2014: New England Journal of Medicine
https://www.readbyqxmd.com/read/25024076/front-line-transplantation-program-with-lenalidomide-bortezomib-and-dexamethasone-combination-as-induction-and-consolidation-followed-by-lenalidomide-maintenance-in-patients-with-multiple-myeloma-a-phase-ii-study-by-the-intergroupe-francophone-du-my%C3%A3-lome
#14
MULTICENTER STUDY
Murielle Roussel, Valérie Lauwers-Cances, Nelly Robillard, Cyrille Hulin, Xavier Leleu, Lotfi Benboubker, Gérald Marit, Philippe Moreau, Brigitte Pegourie, Denis Caillot, Christophe Fruchart, Anne-Marie Stoppa, Catherine Gentil, Soraya Wuilleme, Anne Huynh, Benjamin Hebraud, Jill Corre, Marie-Lorraine Chretien, Thierry Facon, Hervé Avet-Loiseau, Michel Attal
PURPOSE: The three-drug combination of lenalidomide, bortezomib, and dexamethasone (RVD) has shown significant efficacy in multiple myeloma (MM). The Intergroupe Francophone du Myélome (IFM) decided to evaluate RVD induction and consolidation therapies in a sequential intensive strategy for previously untreated transplantation-eligible patients with MM. PATIENTS AND METHODS: In this phase II study, 31 symptomatic patients age < 65 years were enrolled to receive three RVD induction cycles followed by cyclophosphamide harvest and transplantation...
September 1, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/24941833/-safety-and-efficacy-of-subcutaneous-administration-of-bortezomib-in-the-treatment-of-multiple-myeloma
#15
Yan-sheng Wang, Shi-hua Ding, Fan Wu, Zhi-tao Wang, Qiang-sheng Wang
OBJECTIVE: To analyze the efficacy and safety of subcutaneous administration of bortezomib in the treatment of multiple myeloma (MM) patients. METHODS: A total of 26 MM patients were enrolled in this study and treated with BDT (bortezomib-dexamethasone-thalidomide). In the 26 MM patients, 12 patients received subcutaneous administration of Bortezomib while 14 patients received conventional intravenous administration. The outcomes and adverse effects of two groups were retrospectively evaluated and compared...
May 2014: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://www.readbyqxmd.com/read/24888806/combination-of-international-scoring-system-3-high-lactate-dehydrogenase-and-t-4-14-and-or-del-17p-identifies-patients-with-multiple-myeloma-mm-treated-with-front-line-autologous-stem-cell-transplantation-at-high-risk-of-early-mm-progression-related-death
#16
Philippe Moreau, Michele Cavo, Pieter Sonneveld, Laura Rosinol, Michel Attal, Annalisa Pezzi, Hartmut Goldschmidt, Juan Jose Lahuerta, Gerald Marit, Antonio Palumbo, Bronno van der Holt, Joan Bladé, Maria Teresa Petrucci, Kai Neben, Jesus san Miguel, Francesca Patriarca, Henk Lokhorst, Elena Zamagni, Cyrille Hulin, Norma Gutierrez, Thierry Facon, Denis Caillot, Lotfi Benboubker, Jean-Luc Harousseau, Xavier Leleu, Hervé Avet-Loiseau, Jean-Yves Mary
PURPOSE: To construct and validate among patients with multiple myeloma (MM) who were treated with intensive therapy a prognostic index of early MM progression-related death. PATIENTS AND METHODS: Patient-level data from the Intergroupe Francophone du Myélome (IFM) 2005-01 trial (N = 482) were used to construct the prognostic index. The event was MM progression-related death within 2 years from treatment initiation. The index was validated using data from three other trials: the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) 26866138-MMY-3006 trial (N = 480), the Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA)-GEMMENOS65 trial (N = 390), and the Hemato-Oncologie voor Volwassenen Nederland (HOVON) -65/German-Speaking Myeloma Multicenter Group (GMMG) -HD4 trial (N = 827)...
July 10, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/23994781/evolving-strategies-with-immunomodulating-drugs-and-tandem-autologous-allogeneic-hematopoietic-stem-cell-transplantation-in-first-line-high-risk-multiple-myeloma-patients
#17
MULTICENTER STUDY
Mauricette Michallet, Mohamad Sobh, Jean El-Cheikh, Stéphane Morisset, Anne Sirvent, Oumedaly Reman, Jérôme Cornillon, Reza Tabrizi, Noel Milpied, Jean-Luc Harousseau, Hélène Labussière, Franck-Emmanuel Nicolini, Michel Attal, Philippe Moreau, Mohamad Mohty, Didier Blaise, Hérvé Avet-Loiseau
We prospectively evaluated in high-risk myeloma patients the efficacy and toxicity of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) followed by reduced-intensity conditioning (RIC) and allogeneic (allo)-HSCT with bortezomib and donor lymphocyte infusions introduction after allo-HSCT (group 1). Results were compared with results from tandem auto-RIC-allo-HSCT without bortezomib (group 2). Groups 1 and 2 were compared to matched patients not receiving allo-HSCT from the Intergroupe Francophone du Myélome prospective studies...
December 2013: Experimental Hematology
https://www.readbyqxmd.com/read/23921945/efficacy-and-safety-profile-of-long-term-exposure-to-lenalidomide-in-patients-with-recurrent-multiple-myeloma
#18
MULTICENTER STUDY
Guillemette Fouquet, Stéphanie Tardy, Hélène Demarquette, Sarah Bonnet, Julie Gay, Houria Debarri, Charles Herbaux, Stéphanie Guidez, Jessica Michel, Aurore Perrot, Caroline Serrier, Darko Miljkovic, Hervé Avet Loiseau, Thierry Facon, Cyrille Hulin, Xavier Leleu
BACKGROUND: Lenalidomide in combination with dexamethasone (Len/Dex) is indicated for patients with recurrent/refractory multiple myeloma (RRMM) who were treated with 1 prior therapy until evidence of disease progression. The objective of the current study was to determine the efficacy and safety profile of long-term exposure to Len/Dex. METHODS: A total of 50 patients with RRMM who were treated with long-term Len for ≥ 2 years from 2 Intergroupe Francophone du Myélome (IFM) centers (Lille and Nancy) were included in the current study...
October 15, 2013: Cancer
https://www.readbyqxmd.com/read/23892719/deletion-of-the-1p32-region-is-a-major-independent-prognostic-factor-in-young-patients-with-myeloma-the-ifm-experience-on-1195-patients
#19
B Hebraud, X Leleu, V Lauwers-Cances, M Roussel, D Caillot, G Marit, L Karlin, C Hulin, C Gentil, F Guilhot, L Garderet, T Lamy, S Brechignac, B Pegourie, J Jaubert, M Dib, A-M Stoppa, C Sebban, C Fohrer, J Fontan, C Fruchart, M Macro, F Orsini-Piocelle, G Lepeu, C Sohn, J Corre, T Facon, P Moreau, M Attal, H Avet-Loiseau
Deletions of the 1p region appear as a pejorative prognostic factor in multiple myeloma patients (especially 1p22 and 1p32 deletions) but there is a lack of data on the real impact of 1p abnormalities on an important and homogeneous group of patients. To address this issue we studied by fluorescence in situ hybridization (FISH) the incidence and prognostic impact of 1p22 and 1p32 deletions in 1195 patients from the IFM (Institut Francophone du Myélome) cell collection. Chromosome 1p deletions were present in 23...
March 2014: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/23796999/chromosomal-abnormalities-are-major-prognostic-factors-in-elderly-patients-with-multiple-myeloma-the-intergroupe-francophone-du-my%C3%A3-lome-experience
#20
Hervé Avet-Loiseau, Cyrille Hulin, Loic Campion, Philippe Rodon, Gerald Marit, Michel Attal, Bruno Royer, Mamoun Dib, Laurent Voillat, Didier Bouscary, Denis Caillot, Marc Wetterwald, Brigitte Pegourie, Gerard Lepeu, Bernadette Corront, Lionel Karlin, Anne-Marie Stoppa, Jean-Gabriel Fuzibet, Xavier Delbrel, Francois Guilhot, Brigitte Kolb, Olivier Decaux, Thierry Lamy, Laurent Garderet, Olivier Allangba, Francois Lifermann, Bruno Anglaret, Philippe Moreau, Jean-Luc Harousseau, Thierry Facon
PURPOSE: Chromosomal abnormalities, especially t(4;14) and del(17p), are major prognostic factors in patients with multiple myeloma (MM). However, this has been especially demonstrated in patients age < 66 years treated with intensive approaches. The goal of this study was to address this issue in elderly patients treated with conventional-dose chemotherapy. PATIENTS AND METHODS: To answer this important question, we retrospectively analyzed a series of 1,890 patients (median age, 72 years; range, 66 to 94 years), including 1,095 with updated data on treatment modalities and survival...
August 1, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
162629
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"